סלספט 500 מג ישראל - עברית - Ministry of Health

סלספט 500 מג

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - טבליות מצופות פילם - mycophenolate mofetil 500 mg - mycophenolic acid

דיפרוספאן זריקה ישראל - עברית - Ministry of Health

דיפרוספאן זריקה

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - תרחיף להזרקה - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.

וייזין אוריגינל טיפות עיניים ישראל - עברית - Ministry of Health

וייזין אוריגינל טיפות עיניים

j-c health care ltd - tetrahydrozoline hydrochloride - טיפות עיניים - tetrahydrozoline hydrochloride 0.05 % - tetryzoline - tetryzoline - relief from soreness, burning, itching, irritation redness due to congestion of the eyes.

טיגציל ישראל - עברית - Ministry of Health

טיגציל

pfizer pharmaceuticals israel ltd - tigecycline - אבקה מיובשת בהקפאה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

טיגציל ישראל - עברית - Ministry of Health

טיגציל

pfizer pfe pharmaceuticals israel ltd - tigecycline - אבקה להכנת תמיסה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

קיוביצין 500 מ"ג ישראל - עברית - Ministry of Health

קיוביצין 500 מ"ג

medison pharma ltd - daptomycin 500 mg/vial - lyophilized powder for injection - daptomycin - cubicin (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-resistant strains) streptococcus pyogenes streptococcus agalactiae streptococcus dysgalactiae subsp. equisimilis and enterococcus faecalis (vancomycin-susceptible strains only). combination therapy may be clinically indicated if the documented or presumed pathogens include gram-negative or anaerobic organisms. daptomycin is not indicated for the treatment of pneumonia. appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. empiric therapy may be initiated while awaiting test results. antimicrobial therapy should be adjusted as needed based upon test results. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cubici

מטוג'קט 50 מג  מל תת עורי ישראל - עברית - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי ישראל - עברית - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי ישראל - עברית - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי ישראל - עברית - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate